Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original): A composition which comprises a pharmaceutically acceptable salt of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, a cosolvent, and surfactant.

Claim 2. (Original): A composition according to claim 1, which further comprises water.

Claim 3. (Original): A composition according to claim 2, which is in the form of a solution.

Claim 4. (Original): A composition according to claim 3, in which the cosolvent is a member, selected from the group, consisting of propylene glycol, polyethylene glycol 400 and glycerin.

Claim 5. (Original): A composition according to claim 3, in which the surfactant is a member, selected from the group, consisting of a polysorbate, a polyoxypropylene-polyoxyethylene block copolymer and a polyethoxylated castor oil.

Claim 6. (Original): A composition according to claim 3, which further comprises an antioxidant.

Claim 7. (Original): A composition according to claim 6, in which the antioxidant is a member, selected from the group, consisting of ascorbic acid, a tocopherol, sodium sulfite, sodium metabisulfite, glutathione, thiourea, L-cysteine hydrochloride monohydrate, N-acetylcysteine and a monothioglycerol.

Claim 8. (Original): A composition according to claim 6, which further comprises a buffer.

Claim 9. (Original): A composition according to claim 8, in which the buffer is a member, selected from the group, consisting of a glycine buffer and a phosphate buffer.

Claim 10. (Original): A composition according to claim 8, in which the pharmaceutically acceptable salt of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid is the potassium salt.

Claim 11. (Original): A composition according to claim 8, in which the cosolvent is polyethylene glycol 400.

Claim 12. (Original): A composition according to claim 11, in which the surfactant is a polysorbate.

Claim 13. (Original): A composition according to claim 12, in which the antioxidant is a monothioglycerol.

Claim 14. (Original): A composition according to claim 13, in which the buffer is a glycine buffer.

Claim 15. (Original): A composition according to claim 14, which further comprises a glass container, selected from the group, consisting of a vial and an ampoule.

Claim 16. (Original): A composition according to claim 15, characterized in that the solution is disposed in the glass container.

Claim 17. (Original): A method for minimizing the chemical degradation of the potassium salt of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid in an aqueous solution comprising the said salt, which method comprises adjusting the pH value of the aqueous solution to between about 8.5 and about 10.5.

Claim 18. (Original): A method for increasing the local tolerance while parenterally administering a composition comprising the potassium salt of 5-methyl-2-(2'-chloro-6'-flouro-anilino)phenylacetic acid, which method comprises administering the said salt in the form of an aqueous solution that also comprises a cosolvent.

Claim 19. (Original): A method according to claim 18, characterized in that the cosolvent is polyethylene glycol 400.

Claim 20. (Original): A method for the treatment of a cyclooxygenase-2-mediated disorder or condition, which comprises parenterally administering a composition according to claim 1.

Claim 21. (Currently amended): A method ~~according to claim 20~~ for the treatment of a cyclooxygenase-2-mediated disorder or condition, which comprises parenterally administering a composition according to claim 14.